Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infiltrating Bladder Urothelial Carcinoma × pembrolizumab × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡